WuXi PharmaTech (药明康德) reported upbeat Q2 financial results, saying that demand continues strong for its services, which drove revenues and earnings higher. Because the company feels increasingly optimistic about its financial prospects, it also issued higher guidance for the full year. WuXi saw its growth rate drop to just 7% in 2009, despite large capital expenditures to offer new lines of business, and it took a $50 million writedown of its AppTech acquisition in 2008. Now, it expects solid increases in the future. More details...

Stock Symbol: (NYSE: WX)